SCHEMBL1623729

SCHEMBL1623729

O=C(NCCN1CCOCC1)[C@H]1CCCN(c2ccc(Cl)c(-c3nc4ccccc4[nH]3)c2)C1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.47
NPC1 O15118 2/20 0.47
ALDH1A1 P00352 5/20 0.47
KDM4E B2RXH2 5/20 0.46
RAB9A P51151 3/20 0.46
HTT P42858 1/20 0.46
HSD17B10 Q99714 4/20 0.43
TSHR P16473 2/20 0.43
TP53 P04637 2/20 0.43
GAA P10253 1/20 0.42
CYP2C9 P11712 1/20 0.41
POLB P06746 1/20 0.41
MAPK1 P28482 1/20 0.41
DUSP3 P51452 1/20 0.41
PTPN5 P54829 1/20 0.41
PTPN11 Q06124 1/20 0.41
HPGD P15428 1/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1625632 1.00 SMN1; SMN2 (0.47) SMN1; SMN2NPC1ALDH1A1KDM4ERAB9A
SCHEMBL1625593 0.96 SMN1; SMN2 (0.48) SMN1; SMN2NPC1ALDH1A1KDM4ERAB9A
SCHEMBL1623594 0.94 CYP1A2 (0.43) SMN1; SMN2NPC1RAB9ATSHRTP53
SCHEMBL1625655 0.91 SMN1; SMN2 (0.46) SMN1; SMN2NPC1ALDH1A1RAB9AHSD17B10
SCHEMBL1623736 0.91 SMN1; SMN2 (0.51) SMN1; SMN2NPC1ALDH1A1KDM4ERAB9A
SCHEMBL1284004 0.91 SMN1; SMN2 (0.46) SMN1; SMN2NPC1ALDH1A1RAB9AHSD17B10
SCHEMBL1284850 0.91 SMN1; SMN2 (0.51) SMN1; SMN2NPC1ALDH1A1KDM4ERAB9A
SCHEMBL1623790 0.89 SMN1; SMN2 (0.47) SMN1; SMN2NPC1ALDH1A1KDM4ERAB9A
SCHEMBL1625628 0.86 SMN1; SMN2 (0.47) SMN1; SMN2NPC1RAB9AHSD17B10TSHR
SCHEMBL1623983 0.86 ALDH1A1 (0.46) SMN1; SMN2NPC1ALDH1A1KDM4ERAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8835648-B2 Hedgehog pathway antagonists and therapeutic applications thereof SIENA BIOTECH S.P.A. (IT) 2014-09-16 US disclosed
US-8835648-B2 Hedgehog pathway antagonists and therapeutic applications thereof SIENA BIOTECH S.P.A. (IT) 2014-09-16 US disclosed
US-20120088752-A1 HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF SIENA BIOTECH S.P.A. (IT) 2012-04-12 US disclosed
US-20120088752-A1 HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF SIENA BIOTECH S.P.A. (IT) 2012-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088752-A1 HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF SHH, GLI1, SMO SMN1; SMN2 2687/4885NPC1 380/4885ALDH1A1 2448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.